Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 14/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | STK17B | O94768 | 1/20 | 0.35 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.32 |
| ▸ | NPR3 | P17342 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14976585 | 0.89 | SYK (0.42) | SYKMEN1KMT2ASTK17BSTK17A | |
| SCHEMBL14976237 | 0.82 | GPR119 (0.37) | SYKMEN1KMT2ANPR3 | |
| SCHEMBL14975655 | 0.80 | SYK (0.38) | SYKMEN1KMT2ALCKJAK3 | |
| SCHEMBL14976306 | 0.79 | SYK (0.36) | SYKMEN1KMT2ABTK | |
| SCHEMBL14976217 | 0.79 | GPR119 (0.37) | SYKMEN1KMT2A | |
| SCHEMBL14975788 | 0.78 | KMT2A (0.40) | MEN1KMT2A | |
| SCHEMBL14976522 | 0.77 | GPR119 (0.38) | SYKMEN1KMT2A | |
| SCHEMBL14976833 | 0.76 | MAPT (0.40) | MEN1KMT2APIN1 | |
| SCHEMBL14975738 | 0.75 | SYK (0.35) | SYKMEN1KMT2ALCKJAK3 | |
| SCHEMBL14976853 | 0.75 | SYK (0.35) | SYKLCKJAK3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013078254-A1 | BICYCLIC HETEROARYL DERIVATIVES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2013-05-30 | — | — | WO | disclosed |